Is there a generic for Foscarnet sodium?

Yes. The FDA Orange Book lists 7 approved generic (ANDA) applications for Foscarnet sodium, referencing the brand FOSCAVIR. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Foscarnet sodium?

FOSCAVIR (NDA 020068, CLINIGEN HLTHCARE) is the reference-listed drug — the approved product a generic applicant must show its version is the same as.

What dosage forms of Foscarnet sodium are approved?

Foscarnet sodium is approved in the following dosage form: solution.

FDA Orange Book · active-ingredient family

Foscarnet sodium

Foscarnet sodium is approved as 1 brand and 7 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:FOSCAVIR · NDA 020068

Brand (NDA)

Generics (ANDA)

Listed patents

Exclusivity periods

Brand (NDA) products · solution

Product	Applicant	Application	TE	Approved
FOSCAVIRRLD×2	CLINIGEN HLTHCARE	NDA 020068	AP	Sep 27, 1991

Generic (ANDA) products (7)

Product	Applicant	Application	TE	Approved
FOSCARNET SODIUM	CAPLIN	ANDA 220068	AP	May 13, 2026
FOSCARNET SODIUM	AMNEAL	ANDA 216602	AP	Mar 01, 2024
FOSCARNET SODIUM	SCIECURE	ANDA 213987	AP	Nov 29, 2023
FOSCARNET SODIUM	AVET LIFESCIENCES	ANDA 213807	AP	Jun 05, 2023
FOSCARNET SODIUM	GLAND	ANDA 213001	AP	Apr 21, 2021
FOSCARNET SODIUM	FRESENIUS KABI USA	ANDA 212483	AP	Jan 29, 2021
FOSCARNET SODIUM×2	HOSPIRA	ANDA 077174	—	May 31, 2005

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Foscarnet sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo